Yousif Capital Management LLC Lowers Stake in Danaher Corporation $DHR

Yousif Capital Management LLC cut its position in shares of Danaher Corporation (NYSE:DHR) by 3.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 69,408 shares of the conglomerate’s stock after selling 2,410 shares during the period. Yousif Capital Management LLC’s holdings in Danaher were worth $13,761,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Ceredex Value Advisors LLC raised its holdings in shares of Danaher by 1.6% during the second quarter. Ceredex Value Advisors LLC now owns 249,377 shares of the conglomerate’s stock valued at $49,262,000 after buying an additional 3,862 shares during the last quarter. Chicago Capital LLC grew its holdings in Danaher by 11.6% in the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock worth $2,634,000 after buying an additional 1,391 shares in the last quarter. Weitz Investment Management Inc. increased its position in Danaher by 6.1% in the 2nd quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock valued at $104,094,000 after acquiring an additional 30,300 shares during the period. UniSuper Management Pty Ltd raised its stake in Danaher by 1.6% during the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock valued at $34,954,000 after acquiring an additional 2,667 shares in the last quarter. Finally, Nvwm LLC boosted its position in Danaher by 20.4% during the 2nd quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock worth $1,401,000 after acquiring an additional 1,204 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on DHR. TD Cowen raised their price target on Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Barclays increased their target price on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Morgan Stanley assumed coverage on shares of Danaher in a research report on Monday, December 1st. They set an “overweight” rating and a $270.00 price target on the stock. Rothschild & Co Redburn reaffirmed a “neutral” rating and issued a $220.00 price target (down from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Finally, Bank of America lowered their price objective on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Twenty-one research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $248.25.

Danaher Price Performance

Shares of NYSE DHR opened at $228.09 on Tuesday. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $258.23. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average of $220.83 and a two-hundred day moving average of $207.36. The company has a market capitalization of $161.11 billion, a price-to-earnings ratio of 47.03, a PEG ratio of 4.36 and a beta of 0.89.

Danaher (NYSE:DHR) last released its earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same period in the previous year, the firm earned $1.71 EPS. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. As a group, analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, December 26th. Danaher’s dividend payout ratio is 26.39%.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the transaction, the senior vice president directly owned 14,553 shares in the company, valued at $3,190,454.19. The trade was a 59.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the sale, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. This trade represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 30,248 shares of company stock valued at $6,609,663 in the last three months. 11.20% of the stock is currently owned by corporate insiders.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.